Literature DB >> 6468014

Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage.

C G Kallenberg, H M Jansen, J D Elema, T H The.   

Abstract

We describe a 38-year-old woman with systemic sclerosis of recent onset and progressive dyspnea. Studies of pulmonary function revealed a restrictive ventilatory disorder with decreased diffusing capacity. Interstitial fibrosis and infiltration with lymphocytes and plasma cells with formation of follicles were observed in the lung biopsy. Analysis of fluid from bronchoalveolar lavage showed an increase in the total number of cells, with a relative increase in neutrophils. Also, the relative amount of the immunoglobulins, IgG and IgM, was increased. During corticosteroid treatment, rapid improvement of pulmonary volumes occurred, together with disappearance of neutrophils and an increase in the percentage of lymphocytes in the lavage fluid. Later on, the total number of cells in the fluid from bronchoalveolar lavage and the percentage of lymphocytes reached normal values. Bronchoalveolar lavage may be of value in assessing and monitoring pulmonary disease in patients with systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6468014     DOI: 10.1378/chest.86.3.489

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Expression of class II MHC antigens on alveolar epithelium in fibrosing alveolitis.

Authors:  C G Kallenberg; B M Schilizzi; F Beaumont; S Poppema; L De Leij; T H The
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

2.  Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study.

Authors:  B Sharada; A Kumar; R Kakker; C M Adya; I Pande; S S Uppal; J N Pande; K R Sunderam; A N Malaviya
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

3.  Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease.

Authors:  R Meliconi; M Bestagno; C Sturani; C Negri; V Galavotti; C Sala; A Facchini; G Ciarrocchi; G Gasbarrini; G C Astaldi Ricotti
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

4.  Polymorphonuclear neutrophil function in systemic sclerosis.

Authors:  L Czirják; K Dankó; S Sipka; M Zeher; G Szegedi
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

5.  Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance.

Authors:  A Scheja; A Akesson; P Wollmer; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

Review 6.  Treatment of systemic sclerosis.

Authors:  T A Medsger
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.